



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q4
2021

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO

February 24, 2022

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q4 2021

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Successful year 2021 with sales and EBITDA at all-time high level



**Sales and EBITDA
at record level**



**Optimization project
"AlzFit 2025" led to
several production
cost reductions and
more efficiency**



**"VERBUND" led to
lower volatility of
prices and predictable
availability of raw
materials**



**Two major
investment projects
in growth and
sustainability
finalized on time and
on budget**



**Q4 was strongly
impacted by all the
challenges around
our supply chain –
costs and availability**



**Management of input
costs and sales prices
will be the #1 topic for
2022**

FINANCIAL OVERVIEW

Key figures




Alzchem Group	Q4 2020	Q4 2021	yoy %	2020 1 - 12	2021 1 - 12	yoy %
SALES (in M€)	100.6	111.1	+10.4%	379.3	422.3	+11.3%
EBITDA (in M€)	12.7	12.5	-1.5%	53.8	62.0	+15.3%
EBITDA margin (in %)	12.6%	11.2%	-1.4pp	14.2%	14.7%	+0.5 pp
Earnings per Share (in €)	0.48	0.58	+20.7%	1.94	2.72	+40.1%

- Strong increase in sales (+11.3%)
- Even stronger increase in EBITDA (+15.3%) despite significant supply chain constraints
- Segments Basics & Intermediates as well as Specialty Chemicals drove topline growth
- Forecasted figures for sales, EBITDA and EBITDA margin could be achieved
- Strong increase in EBITDA Margin (+0.5 pp) and earnings per share (+40.1%)
- Volume and price increase more than compensated for cost increase

SALES ANALYSIS	DELTA Q4	DELTA 01 - 12
Volume	5.0%	9.7%
Price	4.6%	2.4%
Currency	0.7%	-0.7%


IMPLEMENTING OPERATING TARGETS 2021

All targets are either achieved or firmly in sight



TIMELINE OF RESTRICTION PROCESS*

Potential restriction of calcium cyanamide registration in Europe



*reflects our present state of knowledge.

(1) EFSA = European Food Safety Authority, (2) SCHER = Scientific Committee on Health and Environmental Risks, (3) ECHA = European Chemicals Agency

SUSTAINABILITY AND CORPORATE SOCIAL RESPONSIBILITY

Tradition and commitment at the same time



Excellent dealing with people and the environment

Successful reduction of the annual CO₂ emissions by approx. 50,000 tons

Investment of approx. 20 M€ in the protection of the environment

Successful audits of the Trostberg site by the industry initiative "Together for Sustainability"

Commitment to compliance with responsible care guidelines

AGENDA – ANALYST PRESENTATION Q4 2021

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES

The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.


alzchem
group 

BASICS & INTERMEDIATES SEGMENT (in M€)




Sales and EBITDA significantly above prior year

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	10.6%	15.3%
Price	8.8%	5.6%
Currency	0.0%	-0.5%

COMMENTS

- 2021 sales as well as EBITDA significantly above previous year
- Main drivers of the sales growth of ~ 20% were business units agriculture, dicyandiamide and metallurgy
- Successful commissioning of the NITRALZ® capacity expansion as an additional foundation for further growth
- EBITDA growth of ~22% on the one hand supported by a range of process optimization projects; on the other hand burdened by exorbitant cost increases, especially with regard to power supply, raw materials and logistics
- Significant price increases implemented for passing on input cost increases, negative impact via timing



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


High sales and capacity utilization generates over-proportional EBITDA growth




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	2.2%	7.1%
Price	1.8%	0.1%
Currency	1.3%	-0.9%

COMMENTS

- Strong increase in sales and EBITDA
- Sales growth mainly caused by DYHARD®, Creapure® and Dormex®;
- Creamino® volumes increased despite difficult market environment due to COVID-19 pandemic
- Multi purpose plants produced on high level; especially custom manufacturing
- Negative sales impact from USD development
- Availability of raw materials and logistics were one of the major challenges in last quarter



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Stable development in all key figures




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	-5.8%	-2.2%
Price	2.7%	2.7%
Currency	0.0%	0.0%

COMMENTS


- Stable development of sales in 2021
- Accordingly, also stable development of EBITDA
- Some shift in service sectors such as higher media requirements and need for disposal services
- Regular price increase of at least the personnel costs implemented

BALANCE SHEET (in M€)

Increase of balance sheet total and equity ratio




ASSETS



- Increase in assets mainly due to investing activity (non-current assets) and higher business volume (current assets)
- Strong increase of trade receivables following increase in sales; no delays in payments experienced
- Inventory increase results from higher input costs, increased business volume and production to stock to ensure availability


LIABILITIES



- Equity ratio increased from 19.4% to 23.7%. Significant positive impact from annual result of 27.8 M€
- Equity was reduced by dividend payments (7.8 M€); reduction of pension provision due to actuarial assumptions (1.5 M€ net of tax) and the share buyback program (1.0 M€)
- Regular loan and lease repayments reduced non-current liabilities
- Current liabilities developed in line with increased business volume. Trade payables impacted by higher purchasing volume and increased raw material prices

CASHFLOW (in M€)

Strong net cashflow impacted by business growth on both directions



- Net cashflow positively impacted by strong net result but reduced by higher growth of business volume with regard to NWC buildup; leading to high cash inflows in next period
- Investing cashflow with 28.5 M€ almost on prior year level; substantial investments in 2021 include NITRALZ® (capacity expansion), new construction of RTO plant (sustainability) and modernization of power grid and power infrastructure

- Cash outflow for financing activities (-23.6 M€) mainly for repayments of loans and leases (-14.6 M€), dividend payments (-7.8 M€) and share buyback program (-1.0 M€). Credit lines again not in use at the end of the year

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



Implementation of price increases, at least in the amount of the cost increases

SUSTAINABILITY

- Set the path to CO₂ neutral growth and climate neutrality by 2045
- Vision 0 accidents
- Vision 0 waste – promoting circular economy
- Introduction of EU Taxonomy Regulation – Taxonomy compliance
- Organize transition from - NFRD (Nonfinancial Reporting Directive) to CSRD (Corporate sustainability Reporting Directive)

Realization and commissioning of Creapure® capacity expansion

Continue to grow Nitralz® and Creamino® business


Management of COVID-19 effects

OUTLOOK 2022 (in M€)


Parity of cost with price increases will determine EBITDA



SALES



EBITDA



COMMENTS

- Price increases will determine EBITDA – balance short term needs with long-term requirements
- Further growth of NITRALZ® and Creamino® business
- Stable development in the agricultural, steel and automotive sectors
- On-time commissioning of Creapure® capacities
- Continued high input costs (raw material, power, logistics) and volatility
- USD exchange rate 1.15

FINANCIAL CALENDAR

Upcoming dates



FEB 24	2022	Annual Report 2021
APR 28	2022	Quarterly Statement 1 st Quarter 2022
MAY 5	2022	Annual General Meeting 2022
MAY 23 - 24	2022	German Spring Conference
JUL 26	2022	Half-Year Financial Report 2022
SEP 5 - 6	2022	Fall Conference
SEP 19 - 21	2022	Berenberg and Goldman Sachs German Corporate Conference
SEP 19 - 23	2022	Baader Investment Conference
OCT 26	2022	Quarterly Statement 3 rd Quarter 2022
NOV 15 - 16	2022	Münchener Kapitalmarkt Konferenz
NOV 28 - 30	2022	Deutsches Eigenkapitalforum

**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q4 2021

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2020	31.12.2021	Deviation	
Intangible assets	1,810	2,329	519	28.7%
Tangible assets	175,062	178,806	3,744	2.1%
Investment properties				
Right of use (assets)	8,524	7,686	-839	-9.8%
Investments accounted for using the equity				
Financials assets	20	20	0	0.0%
Trade receivables				
Other receivables	630	1,320	690	109.6%
<i>there of Deferred tax assets for pensions p</i>				
Deferred tax assets	35,795	34,924	-871	-2.4%
SUM NON-CURRENT ASSETS	221,842	225,086	3,244	1.5%
Inventories	67,402	86,676	19,275	28.6%
Trade receivables	33,124	40,841	7,717	23.3%
Financial assets	0		0	-100.0%
Other receivables	13,501	16,454	2,952	21.9%
Income tax receivables	1,311	326	-986	-75.2%
Cash and cash equivalents	17,117	8,285	-8,832	-51.6%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	132,456	152,581	20,126	15.2%
SUM ASSETS	354,298	377,667	23,370	6.6%

ALZCHEM GROUP (IN T€)	31.12.2020	31.12.2021	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	81,356	101,127	19,772	24.3%
Other comprehensive income	-53,077	-51,104	1,973	-3.7%
Own shares		-1,009	-1,009	
SHARE TO THE SHAREHOLDERS	66,895	87,630	20,736	31.0%
Non-controlling interests	1,763	1,934	171	9.7%
SUM EQUITY	68,658	89,565	20,907	30.5%
Provisions for pensions	141,775	140,005	-1,769	-1.2%
Other provisions	24,233	24,372	139	0.6%
Loans	48,042	37,553	-10,490	-21.8%
Finance lease liabilities	6,680	5,793	-887	-13.3%
Trade liabilities				
Other liabilities	342	171	-171	-50.0%
Deferred tax liabilities	4,695	4,084	-611	-13.0%
SUM NON-CURRENT LIABILITIES	225,767	211,979	-13,789	-6.1%
Other provisions	2,877	2,968	91	3.2%
Loans	12,704	10,490	-2,214	-17.4%
Finance lease liabilities	1,634	1,805	170	10.4%
Finance liabilities	0		0	-100.0%
Trade liabilities	20,880	32,780	11,899	57.0%
Other liabilities	21,583	26,220	4,636	21.5%
Income tax liabilities	193	1,862	1,668	862.3%
SUM CURRENT LIABILITIES	59,872	76,124	16,252	27.1%
Sum EQUITY AND LIABILITIES	354,298	377,667	23,370	6.6%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Adjustment of market interest rate from 0.5 % → 1.0 %; decreasing impact on provision
- Adjustment of expected pension trend from 1.5 % → 2.0 %; increasing impact on provision
- Adjustment of expected salary trend from 2.5 % → 3.0 %; increasing impact on provision
- Moderately increasing cash payments

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Deviation (Q4)	Dez. 20	Dez. 21	Dev. YOY
Revenue	94,740	102,511	81,373	100,634	104,321	111,000	95,920	111,052	10,418 10%	379,257	422,293	43,036 43%
Increase (+) / Decrease (-) in inventories of finished goods	2,152	-3,162	3,295	-4,800	-2,144	-1,621	6,350	7,442	12,242 -255%	-2,514	10,028	12,541 -261%
Other income	2,425	2,648	2,732	2,866	3,983	2,505	2,143	2,729	-137 -5%	10,671	11,360	689 24%
Raw materials and consumables used	-35,491	-35,253	-29,903	-31,860	-36,226	-37,538	-42,153	-54,753	-22,893 72%	-132,507	-170,671	-38,164 120%
Employee benefits expense	-32,509	-31,733	-29,033	-34,133	-33,038	-35,209	-30,875	-33,045	1,089 -3%	-127,409	-132,166	-4,758 14%
Other expense	-19,002	-18,190	-16,477	-20,024	-20,175	-20,143	-17,548	-20,932	-908 5%	-73,693	-78,798	-5,104 25%
EBITDA	12,315	16,822	11,986	12,683	16,722	18,993	13,838	12,493	-190 -1%	53,806	62,046	8,241 65%
Depreciation expense	-5,582	-5,742	-5,669	-6,104	-5,771	-5,900	-6,206	-6,598	-494 8%	-23,097	-24,475	-1,378 23%
Impairment												
EBIT	6,734	11,080	6,318	6,578	10,951	13,094	7,632	5,895	-683 -10%	30,709	37,572	6,862 104%
Investment income	5	20	103	6	5	0	12	0	-6 -99%	134	17	-117 -1918%
Other interest and similar income	620	-453	14	10	507	244	127	-252	-262 <-1.000%	191	626	435 4532%
Other interest and similar expense	-874	-925	-1,088	-948	-425	-413	-431	-434	514 -54%	-3,835	-1,703	2,132 -225%
Financial result	-248	-1,358	-971	-932	88	-169	-292	-686	246 -26%	-3,510	-1,060	2,450 -263%
Result from associates												
Result from ordinary business	6,485	9,721	5,347	5,646	11,039	12,924	7,340	5,209	-437 -8%	27,199	36,512	9,312 165%
Taxes on income and profit	-2,063	-2,970	-1,542	-759	-3,109	-3,710	-2,608	679	1,438 -189%	-7,334	-8,748	-1,415 186%
<i>thereof income tax</i>	-1,630	-3,300	-1,241	-814	-2,737	-3,330	-1,944	-1,036	-222 27%	-6,985	-9,047	-2,062 253%
<i>thereof change from deferred taxes</i>	-433	330	-301	55	-373	-380	-663	1,715	1,660 >1.000%	-349	298	647 1185%
Annual result	4,422	6,752	3,805	4,887	7,930	9,214	4,733	5,887	1,001 20%	19,866	27,763	7,898 162%
<i>thereof minority interests</i>	43	43	43	43	43	43	43	43		171	171	
<i>thereof shares held by shareholders</i>	4,380	6,709	3,762	4,844	7,887	9,171	4,690	5,844	1,001 21%	19,695	27,592	7,898 163%
Result per share in EUR	0.43 €	0.66 €	0.37 €	0.48 €	0.78 €	0.90 €	0.46 €	0.58 €		1.94 €	2.72 €	

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

	Q4 2020	Q4 2021	Deviation (QoQ)		YTD Dez.2020	YTD Dez.2021	Deviation (YoY)	
Revenue	100,634	111,052	10,418	10.4%	379,257	422,293	43,036	11.3%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-4,800	7,442	12,242	-255.0%	-2,514	10,028	12,541	-498.9%
Other income	2,866	2,729	-137	-4.8%	10,671	11,360	689	6.5%
Raw materials and consumables used	-31,860	-54,753	-22,893	71.9%	-132,507	-170,671	-38,164	28.8%
Employee benefits expense	-34,133	-33,045	1,089	-3.2%	-127,409	-132,166	-4,758	3.7%
Other expense	-20,024	-20,932	-908	4.5%	-73,693	-78,798	-5,104	6.9%
EBITDA	12,683	12,493	-190	-1.5%	53,806	62,046	8,241	15.3%
Depreciation expense	-6,104	-6,598	-494	8.1%	-23,097	-24,475	-1,378	6.0%
Impairment	0	0	0		0	0	0	
EBIT	6,578	5,895	-683	-10.4%	30,709	37,572	6,862	22.3%
Investment income	6	0	-6	-99.1%	134	17	-117	-87.1%
Other interest and similar income	10	-252	-262	<-1.000%	191	626	435	227.6%
Other interest and similar expense	-948	-434	514	-54.2%	-3,835	-1,703	2,132	-55.6%
Financial result	-932	-686	246	-26.4%	-3,510	-1,060	2,450	-69.8%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	5,646	5,209	-437	-7.7%	27,199	36,512	9,312	34.2%
Taxes on income and profit	-759	679	1,438	-189.4%	-7,334	-8,748	-1,415	19.3%
<i>thereof income tax</i>	-814	-1,036	-222	27.3%	-6,985	-9,047	-2,062	29.5%
<i>thereof change from deferred taxes</i>	55	1,715	1,660	>1.000%	-349	298	647	-185.6%
Annual result	4,887	5,887	1,001	20.5%	19,866	27,763	7,898	39.8%
<i>thereof minority interests</i>	43	43	0	0.0%	171	171	0	0.0%
<i>thereof shares held by shareholders</i>	4,844	5,844	1,001	20.7%	19,695	27,592	7,898	40.1%
Result per share in EUR	0.48 €	0.58 €	0	20.7%	1.94 €	2.72 €	1	40.1%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

Consolidated earnings before taxes
Depreciation on fixed and intangible assets
Decrease in pension provisions
Loss (+) / Profit (-) from the sale of non-current assets
Other non-cash income (-) and expenses (+)
Financial result
Interests & Taxes
Increase (+) / Decrease (-) Net Working Capital
Cashflow from ongoing operations (Net cash flow)
Cash outflows for investments in fixed assets
Cash inflows from the sale of fixed assets
Cash inflow from the acquisition / Reverse acquisition
Cashflow from investing activity
Free cashflow
Deposits (+) / Repayment (-) bank loans long-term
Repayment of bank loans long-term
Deposits (+) / Repayment (-) from short-term financing lines
Dividend payments
Payment of reduction in leasing liabilities
Payments for the acquisition of own shares (incl. transaction costs)
Payments to non-controlling interests
Cashflow from financing activity
Net increase / decrease in cash and cash equivalents

Q4 2020	Q4 2021
5,644	5,209
6,104	6,598
-281	-344
0	-40
5,285	2,020
933	686
-2,141	-1,249
-621	5,211
14,923	18,090
-12,803	-6,855
-2	40
-12,804	-6,815
2,119	11,275
10,000	
-2,983	-3,449
-4,001	-6,024
-610	-497
2,406	-9,969
4,525	1,307

1 - 12 2020	1 - 12 2021
27,198	36,512
23,097	24,475
-1,182	-1,419
-3	-50
7,857	4,177
3,510	1,060
-11,500	-7,341
-267	-14,398
48,710	43,016
-28,832	-28,535
3	56
-28,829	-28,479
19,881	14,537
10,000	
-11,934	-12,704
-1	
-7,632	-7,821
-1,996	-1,911
	-1,013
-171	-171
-11,734	-23,620
8,147	-9,083

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

	2019				2020				2021				YTD Q4 2021					
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q4)		PY T€	Actual T€	Deviation PY (YOY)	
													T€	%			T€	%
Basics & Intermediates	35,465	37,844	41,693	34,405	36,012	38,266	32,320	39,837	41,070	45,178	42,465	47,561	7,724	16%	146,434	176,274	29,840	20%
Specialty Chemicals	50,063	51,686	50,952	47,321	52,199	57,854	42,995	54,383	56,775	59,330	47,116	57,279	2,896	5%	207,431	220,499	13,068	6%
Other and Holding	6,595	6,591	6,786	6,672	6,529	6,391	6,058	6,414	6,477	6,492	6,339	6,212	-202	-3%	25,392	25,521	129	1%
Group Consolidation			0															
Alzchem Group	92,124	96,120	99,430	88,398	94,740	102,511	81,373	100,634	104,321	111,000	95,920	111,052	10,418	9%	379,257	422,293	43,036	11%

EBITDA

	2019				2020				2021				YTD Q4 2021					
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q4)		PY T€	Actual T€	Deviation PY (YOY)	
													T€	%			T€	%
Basics & Intermediates	1,038	628	3,220	360	1,903	2,485	2,006	2,587	2,791	3,826	3,118	1,250	-1,336	-107%	8,981	10,985	2,005	22%
Specialty Chemicals	11,711	12,919	9,218	7,837	10,158	14,457	9,418	10,092	13,947	14,801	10,096	11,820	1,728	15%	44,125	50,664	6,539	15%
Other and Holding	357	838	1,435	1,877	317	81	361	230	435	-43	512	502	271	54%	989	1,405	417	42%
Group Consolidation	125	239	-309	-1,414	-63	-201	202	-227	-451	409	112	-1,079	-853	79%	-289	-1,008	-720	249%
Alzchem Group	13,231	14,623	13,564	8,659	12,315	16,822	11,986	12,683	16,722	18,993	13,838	12,493	-190	-2%	53,806	62,046	8,241	15%

EXECUTIVE TEAM

Alzchem Group AG



ANDREAS NIEDERMAIER

CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY

Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

KLAUS ENGLMAIER

COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY

Production, Engineering, Environment/Safety/Health/Quality, Technology

DR. GEORG WEICHSELBAUMER

CSO

WITH ALZCHEM SINCE 2012


AREAS OF RESPONSIBILITY

Marketing, Sales, Innovation Management & Process Development, R&D, Product Safety and Approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS

POPULATION GROWTH

LONGER LIFE EXPECTANCY

CLIMATE CHANGE

SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES		Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
		Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
		Reduction of methane emissions during storage of manure	Agriculture
		Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, MBCC Group, Firmenich, Aramark, VIActiv)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		

KEY SHARE DATA

Share Details as of February 22, 2022



SHARES OUTSTANDING 10,176,335
including 40,581 shares held
by Alzchem Group AG

LAST CLOSING PRICE EUR 22.50

MARKET CAPITALIZATION EUR 229 m

TICKER ACT


WKN A2YNT3

ISIN DE000A2YNT30

LISTING Frankfurt Stock Exchange –
Prime Standard

DESIGNATED SPONSOR Baader Bank AG
Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



As of February 2021. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the “Guide to the DAX Equity Indices, i.e. considering the number of 40,581 own shares currently held by the company.”